SpyGlass Pharma, Inc. (SGP) stock
Close on Nov 13, 2026Market cap $1.10BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $1.10B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 5.23
- Dividend yield
- –
- Free cash flow yield
- -5.39%
Fundamentals
- Net income
- -$70.49M
- EPS, diluted
- -$7.73
- Free cash flow
- -$59.23M
- Book value per share
- $6.29
- Diluted shares
- 33M
Trading
- Next earnings
- Mar 25, 2027 (estimated, after the close)
- Previous close
- $33.32
- Open
- $33.88
- Day's range
- $32.12 – $33.88
- Volume
- 39,457
- Average volume (20 days)
- 114,436
- Index membership
- Russell 2000 (since Jun 2026)
- RSI (14 days)
- 55.0
- Volatility (1 year)
- 62.4%
- Relative volume
- 0.36×
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | SGP | S&P 500 | Difference | SGP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +37.5% | -3.0% | +40.5 pts | ||
| 3 months | +30.6% | -2.8% | +33.4 pts | ||
| Year to date | +16.8% | +11.5% | +5.3 pts | ||
| 1 year | +16.8% | +13.5% | +3.3 pts | ||
| 3 years | +16.8% | +77.7% | −60.9 pts | +5.3% | +21.1% |
| 5 years | +16.8% | +72.6% | −55.8 pts | +3.2% | +11.5% |
| 10 years | +16.8% | +308.2% | −291.4 pts | +1.6% | +15.1% |
Three years at a glance
Fiscal years 2023 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases SpyGlass Pharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Update
- Results
- Results
- Results
About SpyGlass Pharma
Surgical & Medical Instruments & Apparatus
SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on developing long-acting, sustained-release drug delivery therapies for chronic ocular conditions. Its primary product candidate in development is the Bimatoprost Drug Pad-IOL System, which combines proprietary drug pads with an intraocular lens to deliver bimatoprost directly during cataract surgery. This system is designed to treat patients with open-angle glaucoma or ocular hypertension by reducing elevated intraocular pressure. The company is also developing a standalone, non-lens, ring-shaped implant to provide sustained bimatoprost delivery for pseudophakic glaucoma patients.
Company profile, executives and historySpyGlass Pharma stock: common questions
What is SpyGlass Pharma's stock price?
SGP closed at $32.88 on Nov 13, 2026, down 1.32% on the day.
What is SpyGlass Pharma's market cap?
SpyGlass Pharma was worth $1.10B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is SGP's P/E ratio?
SpyGlass Pharma lost money over the twelve months to Sep 30, 2026 (diluted EPS -$7.73), so it has no meaningful P/E ratio.
Does SpyGlass Pharma pay a dividend?
No. SpyGlass Pharma has not paid a cash dividend over the last twelve months.
When does SpyGlass Pharma report earnings next?
SpyGlass Pharma is expected to report Q4 FY2026 results on Mar 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has SGP stock performed over the past year?
Including dividends, SGP returned +16.8% over the past year, against +13.5% for the S&P 500.
How many SGP shares are sold short?
1M shares were sold short at the latest FINRA report, 10.45% of the float, or 12.1 days of average trading volume.
Who are SpyGlass Pharma's competitors?
Companies most similar to SpyGlass Pharma by business, industry and size include GKOS, SGHT, PYPD, RTGN, LNSR.
See a number that looks wrong?